Art Fratamico

Art Fratamico has a strong background in the biopharmaceutical industry, with a focus on business development and executive leadership roles. Art currently serves as the President and CEO of Radiant Biotherapeutics, where they are involved in the development of a novel biologic platform called MultabodyTm. Prior to this, Art was a Board Member at Panbela Therapeutics, where they contributed to the development of therapeutics for pancreatic cancer. Art also held the position of Chief Business Officer at Galera Therapeutics, Inc. and Vitae Pharmaceuticals, playing a key role in their strategic planning and transformation. Additionally, Art has held executive positions at Flexion Therapeutics, Trevena Inc, Gemin X Pharmaceuticals, Inc., and MGI Pharma, where they were responsible for business development and licensing efforts.

Art Fratamico completed their Bachelor of Science degree in Pharmacy from the University of the Sciences in Philadelphia between 1983 and 1988. Following this, they pursued further education and obtained an MBA from Drexel University's LeBow College of Business in the field of Finance & Marketing, where they attended from 1991 to 1994.